Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database
Hongtao Liu1, Zhaoyu Li2, Su Yan2
1Guangxi Health Science College, Nanning, China.
Background:
Remimazolam, a novel ultra-short-acting benzodiazepine, has gained popularity in various anesthetic applications due to its pharmacokinetic advantages. However, as its use increases, safety concerns also rise, necessitating thorough examination. Additionally, the limited reports on its side effects require a broader investigation to better understand the drug's safety profile.
Methods:
This observational study systematically investigated adverse drug events (ADEs) associated with remimazolam using the FAERS database from Q1 2020 to Q4 2023. The primary objective was to assess potential safety signals and provide comprehensive information for clinical and regulatory purposes.
Results:
A total of 67 cases and 161 ADEs were identified. The incidence of ADEs was higher in patients aged >45 years, particularly those >65 years. Intravenous general anaesthesia was the most common administration method. Notable ADE signals included serious events such as allergic reactions, respiratory and cardiac arrest, and vascular access occlusion.
Conclusion:
Clinicians should be vigilant about potential allergic reactions to remimazolam, especially in older patients, and avoid off-label use until more data are available. Continuous monitoring of post-market surveillance data is essential for uncovering undetected ADEs and ensuring the safe use of remimazolam.
Editorial Comment:
This study analyzed adverse drug events (ADEs) associated with remimazolam using the FAERS database, identifying serious safety signals like allergic reactions, respiratory and cardiac arrests, and vascular access site occlusions, especially in older patients. The findings highlight the need for vigilant monitoring, cautious off-label use, and ongoing post-marketing surveillance.
Insights
Remimazolam, an ultra-short-acting anesthetic, shows increased adverse events, particularly allergic reactions and cardiac/respiratory issues in older patients. Vigilant monitoring and cautious use are crucial for patient safety.
Area of Science:
- Anesthesiology
- Pharmacovigilance
- Clinical Pharmacology
Background:
- Remimazolam is a novel ultra-short-acting benzodiazepine gaining traction in anesthesia.
- Its increasing use necessitates a comprehensive safety profile evaluation.
- Limited data on side effects warrants broader investigation.
Purpose of the Study:
- To systematically investigate adverse drug events (ADEs) linked to remimazolam.
- To identify potential safety signals using real-world data.
- To inform clinical practice and regulatory actions.
Main Methods:
- Observational study utilizing the FDA Adverse Event Reporting System (FAERS) database.
- Data analyzed from Q1 2020 to Q4 2023.
- Focus on identifying and characterizing ADEs associated with remimazolam.
Main Results:
- 67 cases and 161 ADEs were identified.
- Higher ADE incidence observed in patients over 45, especially those over 65.
- Key safety signals included allergic reactions, respiratory/cardiac arrest, and vascular access occlusion.
Conclusions:
- Clinicians must be alert to remimazolam's potential for allergic reactions, particularly in elderly patients.
- Off-label use should be approached with caution due to limited data.
- Continuous post-market surveillance is vital for detecting and managing ADEs.
Related Concept Videos
01:15REM Sleep Behavior Disorder
RBD is significantly associated with...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...